ID 10010
File
Authors
Koyama, Satoshi Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine Researchers DB
Fujiwara, Kazunori Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine Researchers DB KAKEN
Morisaki, Tsuyoshi Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine
Miyake, Naritomo Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine Researchers DB KAKEN
Fukuhara, Takahiro Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine Researchers DB KAKEN
Takeuchi, Hiromi Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine Researchers DB KAKEN
Keywords
Recurrent and metastatic
Head and neck cancer
Second-line
Successive
Chemotherapy
Abstract
ObjectiveThe increase in treatment options resulted in successful treatment with multiple lines of chemotherapy for recurrent and metastatic (RM) head and neck cancer (HNC). The present study aimed to elucidate the beneficial effect of successive treatment for RM-HNC. MethodsWe included 78 patients with RM-HNC who received one or multiple lines of chemotherapy from January 2008 to December 2019. We divided the patients into three groups according to treatment period: January 2008 to November 2012 included those who underwent cancer chemotherapy only with cytotoxic agents (Tox group), December 2012 to March 2017 included those who received cytotoxic agents and cetuximab (Cet group), and March 2017 to December 2019 included those who received cytotoxic agents, cetuximab and immune checkpoint inhibitor nivolumab (Nivo group). Moreover, we compared the overall survival of the three groups. ResultsIn total, 18, 33, and 27 patients were included in the Tox, Cet, and Nivo groups, respectively. The median overall survival were 8.5 months in the Tox group, 16 months in the Cet group, and 19 months in the Nivo group, and the difference in the result was significant. ConclusionsSuccessive treatment with second and subsequent lines of chemotherapy in patients with RM-HNC improves prognosis.
Publisher
Elsevier B.V.
Content Type
Journal Article
Link
ISSN
03858146
Journal Title
Auris Nasus Larynx
Current Journal Title
Auris Nasus Larynx
Volume
48
Issue
1
Start Page
161
End Page
165
Published Date
2021-02
Publisher-DOI
Text Version
Author
Rights
© 2020 Oto-Rhino-Laryngological Society of Japan Inc. Published by Elsevier B.V. All rights reserved.
Citation
Koyama, Satoshi. Fujiwara, Kazunori. Morisaki, Tsuyoshi. et al. Efficacy of second and subsequent lines of chemotherapy for recurrent and metastatic head and neck cancer. Auris Nasus Larynx. 2021. 48(1), 161-165.
Department
Faculty of Medicine/Graduate School of Medical Sciences/University Hospital
Language
English
pii
S0385-8146(20)30197-8